Data / Form D filings / Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc.: Form D filings
Taysha Gene Therapies, Inc., a biotechnology company in Dallas, TX, filed 4 Form D notices with the SEC between 2020 and 2023. The latest, on August 25, 2023, reports $150 million sold of a $150 million offering to 42 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, Dallas, TX, 75247
- Phone
- (214) 612-0000
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2019
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1806310
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 25, 2023 | New notice | $149,997,018 | $149,952,767 | $44,251 | 42 | Aug 16, 2023 | sec.gov |
| Nov 7, 2022 | New notice | $30,000,000 | $30,000,000 | 1 | Oct 21, 2022 | sec.gov | |
| Aug 18, 2020 | New notice | $95,999,816 | $95,999,816 | 26 | Jul 2, 2020 | sec.gov | |
| May 4, 2020 | New notice | $30,000,000 | $18,000,000 | $12,000,000 | 9 | Mar 4, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Phillip P. Donenberg | Director | |
| Sean P. Nolan | Executive Officer, Director | |
| Laura P. Sepp-Lorenzino | Director | |
| Sean P. Stalfort | Director | |
| Kamran P. Alam | Executive Officer | |
| Kathleen P. Reape | Director | |
| Sukumar P. Nagendran | Executive Officer, Director |
Other biotechnology companies in Texas that filed recently
- Nuclein, LLC $15.7 million · Oct 27, 2026
- OncoNano Medicine, Inc. $10.1 million · Oct 8, 2026
- Solaris Endovascular Inc. $5 million · Oct 1, 2026
- Hera Biotech, Inc. $1.7 million · Sep 23, 2026
- Kayak Therapeutics, Inc. $25 million · Aug 21, 2026
- InnovoTEX Inc. $2.7 million · Aug 18, 2026
Every Form D from the week of Aug 21, 2023 · All recent filings in Texas · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Taysha Gene Therapies, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.